title: Significance of cytogenetic findings for the clinical outcome in patients with T-cell lymphoma of angioimmunoblastic lymphadenopathy type.
abstract: OBJECTIVE
  The aim of this study was to evaluate the significance of cytogenetic findings for the clinical outcome of patients with Angioimmunoblastic Lymphadenopathy (AILD)-Type T-cell lymphoma.
  
  
  METHODS
  In a retrospective analysis, the cytogenetic findings of 50 patients with AILD-type T-cell lymphoma were correlated with the frequency of spontaneous and therapy-induced remissions and with survival using the statistical methods of Kaplan and Meier and the model of Cox for multivariate analysis. Treatment was not uniform because the patients were treated in different hospitals during a period of 8 years and because a standard therapy has not yet been established.
  
  
  RESULTS
  The following cytogenetic findings were associated with a significantly lower incidence of therapy-induced remissions and a significantly shorter survival duration: presence of aberrant metaphases in unstimulated cultures (P = .04 for both parameters); clones with an additional X chromosome (P = .0001 and P = .03, respectively); structural aberrations of the short arm of chromosome 1, preferentially involving 1p31-32 (P < .001 and P = .04, respectively); and complex aberrant clones with more than four aberrations (P = .0003 and P = .005, respectively). Multivariate analysis showed that these cytogenetic findings had a significant influence on survival, but therapy modalities did not. Only the presence of complex aberrant clones was an independent prognostic factor. Trisomy 3 had no effect on survival, but patients without trisomy 5 (P = .08) tended to live longer.
  
  
  CONCLUSIONS
  This is the first study that seems to indicate that cytogenetic findings have prognostic significance in AILD-type T-cell lymphoma. These results must be proven in prospective studies of homogeneously treated patients.
authors.affiliation: Department of Human Genetics, University of Kiel, Germany.
authors.forename: B
authors.initials: B
authors.lastname: Schlegelberger
authors.forename: T
authors.initials: T
authors.lastname: Zwingers
authors.forename: K
authors.initials: K
authors.lastname: Hohenadel
authors.forename: D
authors.initials: D
authors.lastname: Henne-Bruns
authors.forename: N
authors.initials: N
authors.lastname: Schmitz
authors.forename: T
authors.initials: T
authors.lastname: Haferlach
authors.forename: C
authors.initials: C
authors.lastname: Tirier
authors.forename: H
authors.initials: H
authors.lastname: Bartels
authors.forename: R
authors.initials: R
authors.lastname: Sonnen
authors.forename: R
authors.initials: R
authors.lastname: Kuse
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002869:Chromosome Aberrations; D005260:Female; D006801:Humans; D007119:Immunoblastic Lymphadenopathy / Q000235:genetics* / Q000401:mortality / Q000628:therapy; D016399:Lymphoma, T-Cell / Q000235:genetics* / Q000401:mortality / Q000628:therapy; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012074:Remission Induction; D012075:Remission, Spontaneous; D012189:Retrospective Studies